


Customer No. 28880



04-27-06

IFJ

Confirmation No. 9410

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

15

Application Number

10/672,949

Filing Date

September 26, 2003

First Named Inventor

Jamie Marie Davis

Art Unit

1624

Examiner Name

Emily B. Bernhardt

Attorney Docket Number

PC25413A

ENCLOSURES (Check all that apply)

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/
Incomplete ApplicationReply to Missing Parts
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional ApplicationPower of Attorney, Revocation,
Change of Correspondence Address

Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____



Landscape Table on CD



After Allowance Communication to TC

Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify
below):Certificate of Express Mail and return
postcard**Remarks**Authorization to charge the fee and any additional fees as necessary or credit
any overpayment to Deposit Account 23-0455 is hereby given.**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Warner-Lambert Company LLC

Signature

Suzanne M Harvey

Printed name

Suzanne M. Harvey

Date

April 26, 2006

Reg. No.

42,640

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Cerene A. Boudrie

Typed or printed name

Cerene A. Boudrie



Date

April 26, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No. 571-273-8300

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Applicant(s):			Docket No. PC25413A
Serial No. 10/672,949	Filing Date 26-Sep-2003	Examiner Emily B. Bernhardt	Group Art 1624
<p>Invention:</p> <p>Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia</p> <div style="text-align: center;"></div>			
<p>I hereby certify that this <u>Response Under 37 C.F.R. 1.111(a)</u></p> <p style="text-align: right;"><small>(Identify type of correspondence)</small></p> <p>Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450</p> <p>on <u>April 26, 2006</u></p> <p style="text-align: center;"><small>(Date)</small></p> <div style="text-align: right; margin-top: 20px;"><p><u>Cerene A. Boudrie</u></p><p style="text-align: center;"><small>(Typed or Printed Name of Person Mailing Correspondence)</small></p><p></p><p style="text-align: center;"><small>(Signature of Person Mailing Correspondence)</small></p><p><u>ED 758026439 US</u></p><p style="text-align: center;"><small>("Express Mail" Mailing Label Number)</small></p></div>			
<p>Note: Each paper must have its own certificate of mailing</p>			



PC25413A

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : Jamie Marie Davis, et al.

EXAMINER : Emily B. Bernhardt

SERIAL NO. : 10/672,949

ART UNIT : 1624

FILED : September 26, 2003

PAPER NO. :

FOR : Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia

Response Under 37 C.F.R. 1.111(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Communication dated March 30, 2006, the Applicants have resubmitted the "Remarks" section that was included in the reply filed on March 17, 2006. The Applicants appreciate the opportunity to resubmit the "Remarks" section of their reply and respectfully request reconsideration of the above-identified application in view of the following remarks.

Remarks begin on page 2 of this paper.